Why the study?
The comparative risks of all-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease treated with vitamin K antagonists versus factor Xa-inhibitors were unclear.
Do factor Xa-inhibitors reduce all-cause mortality, stroke, and bleeding compared to vitamin K antagonists in patients with atrial fibrillation and valvular heart disease?
Do factor Xa-inhibitors reduce all-cause mortality, stroke, and bleeding compared to vitamin K antagonists in patients with atrial fibrillation and valvular heart disease?
Factor Xa-inhibitors appear as safe and effective as vitamin K antagonists in patients with atrial fibrillation and valvular heart disease, with apixaban showing a lower risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Comparable outcomes support either option in AF with VHD; leaves open need for RCTs to guide choice.
Strange et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: